Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.

  title={Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.},
  author={S. Jyonouchi and Brenda Gwafila and L. A. Gwalani and Maria Ahmad and Chistopher Moertel and Cecil Holbert and J. Kim and N. Kobrinsky and S. Roy-Ghanta and J. Orange},
  journal={Clinical immunology},
  • S. Jyonouchi, Brenda Gwafila, +7 authors J. Orange
  • Published 2017
  • Medicine
  • Clinical immunology
  • BACKGROUND Low dose IL-2 can restore the function of T and NK cells from Wiskott-Aldrich (WAS) patients. However, the safety of in vivo IL-2 in WAS is unknown. OBJECTIVES A phase-I study to assess safety of low dose IL-2 in WAS. METHODS Patients received 5 daily subcutaneous IL-2 injections, every 2months, for three courses. A "3+3" dose escalation method was used. RESULTS 6 patients received the 0.5millionunits/m2/day dose without serious adverse events. However, 2 of 3 patients… CONTINUE READING
    15 Citations
    Low Dose Medicine: theoretical background and scientific evidence
    • 2
    Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome
    • 58
    Primary Immunodeficiency Diseases: Current and Emerging Therapeutics
    • 24
    • PDF
    Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease


    Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
    • 564
    Interleukin-2 and regulatory T cells in graft-versus-host disease.
    • 794
    • PDF